Weekly Research Analysts’ Ratings Changes for Seaport Therapeutics (SPTX)

Seaport Therapeutics (NASDAQ: SPTX) recently received a number of ratings updates from brokerages and research firms:

• 7/15/2026 – Seaport Therapeutics was given a new $50.00 price target by Seaport Research Partners.
• 7/15/2026 – Seaport Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $50.00 price target on the stock.
• 7/15/2026 – Seaport Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $50.00 price target on the stock.
• 7/7/2026 – Seaport Therapeutics is now covered by Wolfe Research. They set a “hold” rating on the stock.
• 6/9/2026 – Seaport Therapeutics was downgraded by UBS Group AG to “sell”.
• 5/27/2026 – Seaport Therapeutics was upgraded by Zacks Research to “hold”.
• 5/26/2026 – Seaport Therapeutics is now covered by Citigroup Inc.. They set a “buy” rating and a $35.00 price target on the stock.
• 5/26/2026 – Seaport Therapeutics was downgraded by BNP Paribas Exane to “market perform”.
• 5/26/2026 – Seaport Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $30.00 price target on the stock.
• 5/26/2026 – Seaport Therapeutics was given a new $42.00 price target by Seaport Research Partners.
• 5/26/2026 – Seaport Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $42.00 price target on the stock.
• 5/26/2026 – Seaport Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $35.00 price target on the stock.

Insider Buying and Selling

In other Seaport Therapeutics news, Director Robert J. Hombach purchased 13,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the purchase, the director owned 13,000 shares in the company, valued at approximately $235,820. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Arch Venture Partners Xii, Llc purchased 1,100,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were acquired at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the acquisition, the insider directly owned 6,294,951 shares in the company, valued at approximately $113,309,118. The trade was a 21.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.